ACE2 News and Research

RSS

Emergent SARS-CoV-2 D614G spike mutation more infective due to "open" morphology

Researchers from the Los Alamos National Laboratory and Duke Human Vaccine Institute & Department of Surgery demonstrated that globally prevalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with the amino acid substitution D614G in the spike protein is much more infective due to profitable binding encounters with the host receptors.

28 Jul 2020

Cat catches coronavirus from owners

Cases of pet animals contracting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported since the coronavirus disease (COVID-19) first emerged. Now, a pet cat has become the first animal in Britain to test positive after contracting the virus from its owners.

28 Jul 2020

High ACE2 Expression on pancreatic islet cells during inflammation could explain new-onset diabetes in COVID-19

A new study suggests that the SARS-CoV-2 infection may be linked to the onset of diabetes, via the infection of pancreatic islet beta cells, which produce insulin.

27 Jul 2020

Scientists develop COVID-19 test to detect neutralizing antibodies with high sensitivity, specificity

According to a study published in Nature Biotechnology, the sVNT is capable of detecting the functional neutralizing antibodies (NAbs) that can block the binding of the coronavirus spike protein to the angiotensin-converting enzyme 2 (ACE2) host receptor, which mimics the virus-host interaction.

25 Jul 2020

Study identifies mechanisms that underlie olfactory symptoms of COVID-19

A new study of human olfactory cells has revealed that viral invasion of supportive cells in the nasal cavity might be driving the loss of smell seen in some patients with COVID-19.

25 Jul 2020

Olfactory cell types are most vulnerable to COVID-19 infection, shows study

Temporary loss of smell, or anosmia, is the main neurological symptom and one of the earliest and most commonly reported indicators of COVID-19.

25 Jul 2020

An important SARS-CoV-2 enzyme is responsible for low in vivo antiviral efficacy of hydroxychloroquine

Researchers have shown that hydroxychloroquine interferes with only one redundant pathway that activates the SARS-CoV-2 spike protein.

24 Jul 2020

Study shows interferons do not induce the expression of SARS-CoV-2 cell entry receptor

In a new bioRxiv study, authors identified a isoform of ACE2 (designated as deltaACE2 or dACE2) receptor, shown to be induced in various human cell types.

23 Jul 2020

Common hypertension drugs do not increase risk of severe, fatal COVID-19 infection

A new Northwestern Medicine study in mice found a widely used class of drugs to treat patients with hypertension, cardiovascular disease and diabetic kidney disease - many of whom are elderly -- does not increase the risk of developing a severe and potentially fatal COVID-19 infection, as previously feared.

22 Jul 2020

Study captures unexpected features of SARS-Cov-2 spike protein

The rod-like spike proteins on the surface of SARS CoV-2 are the tip of the spear of the COVID-19 pandemic.

22 Jul 2020

Lab-made virus infects cells, interacts with antibodies just like SARS-CoV-2

Airborne and potentially deadly, the virus that causes COVID-19 can only be studied safely under high-level biosafety conditions.

21 Jul 2020

Mouse model of fatal COVID-19 developed for vaccine and drug testing

Now, a new study published on the preprint server bioRxiv in July 2020 presents an engineered transgenic mouse that reproduces the functional and clinical characteristics of severe human SARS-CoV-2 infection.

21 Jul 2020

Analysis of the SARS-CoV-2 proteome via visual tools

Now, a new study published on the preprint server bioRxiv* in July 2020 shows how this can be advanced at a greater speed by combining experimental results with homology models obtained by high-throughput pipelines. This will help produce new hypotheses that will show novel druggable targets for effective drug development.

21 Jul 2020

Novel blood test for heart failure could lead to new diagnostics for COVID-19 patients

A new blood test that reliably predicts outcomes for heart failure patients could lead to new diagnostics and treatments for COVID-19 patients as well, according to newly published research from cardiologists at the University of Alberta.

20 Jul 2020

Examining cardiovascular injuries in patients who recovered from COVID-9 infection

The coronavirus disease is wreaking havoc on the health of communities throughout the world and may have lasting cardiac effects on those who have recovered from the virus.

19 Jul 2020

More COVID-19 cases where blood type A is common

Now, a new study by researchers at the University of Ulm, Germany, which is published on the preprint server medRxiv in July 2020, focuses on how blood group distribution is related to the mapped dynamics of the epidemic as shown by its geographical distribution.

17 Jul 2020

New insight into the SARS-CoV-2 infection process

Canadian researchers from the Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, have found that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be using a unique method to gain entry into the cells.

16 Jul 2020

Study shows fused lung cells are pervasive in severe COVID-19

In a recent bioRxiv paper, scientists from Institut Pasteur and other research centers in France demonstrated how pathological effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are modulated by cellular proteins that can either inhibit or facilitate cell fusion and subsequent syncytia formation.

16 Jul 2020

Compelling study shows heparin may protect against COVID-19

A compelling new study conducted by an international team of researchers has demonstrated that the widely used blood-thinning medication - heparin - can block infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

16 Jul 2020

Prominent pharmacologist calls for new approach to treat COVID-19

A prominent Australian pharmacologist has called for a new approach to treating COVID-19 as hopes fade of finding an effective vaccine or antiviral before the end of the year.

16 Jul 2020

ACE2 News and Research

Emergent SARS-CoV-2 D614G spike mutation more infective due to "open" morphology

Cat catches coronavirus from owners

High ACE2 Expression on pancreatic islet cells during inflammation could explain new-onset diabetes in COVID-19

Scientists develop COVID-19 test to detect neutralizing antibodies with high sensitivity, specificity

Study identifies mechanisms that underlie olfactory symptoms of COVID-19

Olfactory cell types are most vulnerable to COVID-19 infection, shows study

An important SARS-CoV-2 enzyme is responsible for low in vivo antiviral efficacy of hydroxychloroquine

Study shows interferons do not induce the expression of SARS-CoV-2 cell entry receptor

Common hypertension drugs do not increase risk of severe, fatal COVID-19 infection

Study captures unexpected features of SARS-Cov-2 spike protein

Lab-made virus infects cells, interacts with antibodies just like SARS-CoV-2

Mouse model of fatal COVID-19 developed for vaccine and drug testing

Analysis of the SARS-CoV-2 proteome via visual tools

Novel blood test for heart failure could lead to new diagnostics for COVID-19 patients

Examining cardiovascular injuries in patients who recovered from COVID-9 infection

More COVID-19 cases where blood type A is common

New insight into the SARS-CoV-2 infection process

Study shows fused lung cells are pervasive in severe COVID-19

Compelling study shows heparin may protect against COVID-19

Prominent pharmacologist calls for new approach to treat COVID-19

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News